J&J’s Tremfya secures two paediatric psoriasis approvals from FDA
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
List view / Grid view
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
Jianbo Diao, PhD, Director of Bioanalytical Services, WuXi AppTec, discusses the importance for mRNA therapy developers of adopting precise and flexible analytical strategies for future pipeline success.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
The innovative approach facilitates QSRR-assisted chromatographic development for N-nitrosamine analysis in pharmaceutical products.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
Extends its digital transformation partnership with Siemens to make greater use of automation, data and AI in its services.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
EMA advisors at the CHMP backed the combination treatment and also recommended Bayer’s menopause drug Lynkuet, putting both on the path to being licensed.
Bioprocess experts from Sartorius BIA Separations and BridgeBio Gene Therapy illustrate an approach with potential to expedite AAV upstream analytics and lower overall process development costs.
The right packaging is critical when it comes to preserving the quality, efficacy and safety of pharmaceutical and nutraceutical products. Here, Uwe Raupbach, R&D Engineer Desiccants, Sanner GmbH, answers some key questions about the need for environmental management in packaging, focusing on moisture and odour control, and the solutions available…
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.